AAAAAA

   
Results: 1-16 |
Results: 16
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins
Authors: Gautschi, O Tschopp, S Olie, RA Leech, SH Simoes-Wust, AP Ziegler, A Baumann, B Odermatt, B Hall, J Stahel, RA Zangemeister-Wittke, U
Citation: O. Gautschi et al., Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins, J NAT CANC, 93(6), 2001, pp. 463
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A0201 restricted epitopes from the human epithelial cell adhesion molecule
Authors: Trojan, A Witzens, M Schultze, JL Vonderheide, RH Harig, S Krackhardt, AM Stahel, RA Gribben, JG
Citation: A. Trojan et al., Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A0201 restricted epitopes from the human epithelial cell adhesion molecule, CANCER RES, 61(12), 2001, pp. 4761-4765
Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells
Authors: Himmelmann, A Gautschi, O Nawrath, M Bolliger, U Fehr, J Stahel, RA
Citation: A. Himmelmann et al., Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells, BR J HAEM, 114(2), 2001, pp. 400-405
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production
Authors: Urosevic, M Kurrer, MO Kamarashev, J Mueller, B Weder, W Burg, G Stahel, RA Dummer, R Trojan, A
Citation: M. Urosevic et al., Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production, AM J PATH, 159(3), 2001, pp. 817-824
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
Authors: Zangemeister-Wittke, U Leech, SH Olie, RA Simoes-Wust, AP Gautschi, O Luedke, GH Natt, F Haner, R Martin, P Hall, J Nalin, CM Stahel, RA
Citation: U. Zangemeister-wittke et al., A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells, CLIN CANC R, 6(6), 2000, pp. 2547-2555
Organizing cancer genetics programs: The Swiss model
Authors: Pichert, G Stahel, RA
Citation: G. Pichert et Ra. Stahel, Organizing cancer genetics programs: The Swiss model, J CL ONCOL, 18(21), 2000, pp. 65S-69S
High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich
Authors: Jost, LM Honegger, HP Stahel, RA
Citation: Lm. Jost et al., High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich, SCHW MED WO, 130(3), 2000, pp. 60-69
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients - A single-center study
Authors: Tscherry, G Jacky, E Jost, LM Stahel, RA
Citation: G. Tscherry et al., Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients - A single-center study, ONCOL-BASEL, 59(2), 2000, pp. 110-117
Ectopic expression of human topoisomerase II alpha fragments and etoposideresistance in mammalian cells
Authors: Ernst, AI Soltermann, A Sigrist, JA Widmer, L Gasser, SM Stahel, RA
Citation: Ai. Ernst et al., Ectopic expression of human topoisomerase II alpha fragments and etoposideresistance in mammalian cells, INT J CANC, 88(1), 2000, pp. 99-107
bcl-xL antisense treatment induces apoptosis in breast carcinoma cells
Authors: Simoes-Wust, AP Olie, RA Gautschi, O Leech, SH Haner, R Hall, J Fabbro, D Stahel, RA Zangemeister-Wittke, U
Citation: Ap. Simoes-wust et al., bcl-xL antisense treatment induces apoptosis in breast carcinoma cells, INT J CANC, 87(4), 2000, pp. 582-590
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment
Authors: Leech, SH Olie, RA Gautschi, O Simoes-Wust, AP Tschopp, S Haner, R Hall, J Stahel, RA Zangemeister-Wittke, U
Citation: Sh. Leech et al., Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment, INT J CANC, 86(4), 2000, pp. 570-576
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
Authors: Olie, RA Simoes-Wust, AP Baumann, B Leech, SH Fabbro, D Stahel, RA Zangemeister-Wittke, U
Citation: Ra. Olie et al., A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy, CANCER RES, 60(11), 2000, pp. 2805-2809
Novel approaches to the treatment of small-cell lung cancer
Authors: Zangemeister-Wittke, U Stahel, RA
Citation: U. Zangemeister-wittke et Ra. Stahel, Novel approaches to the treatment of small-cell lung cancer, CELL MOL L, 55(12), 1999, pp. 1585-1598
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
Authors: Huinink, WWT Bergman, B Chemaissani, A Dornoff, W Drings, P Kellokumpu-Lehtinen, PL Liippo, K Mattson, K von Pawel, J Ricci, S Sederholm, C Stahel, RA Wagenius, G von Walree, N Manegold, C
Citation: Wwt. Huinink et al., Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer, LUNG CANC, 26(2), 1999, pp. 85-94
The cytochrome b(5) tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells
Authors: Soltermann, A Ernst, A Leroy, D Stahel, RA Gasser, SM
Citation: A. Soltermann et al., The cytochrome b(5) tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells, EXP CELL RE, 249(2), 1999, pp. 308-319
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
Authors: Stahel, RA Jost, LM Kroner, T Dommann-Scherrer, C Maurer, R Glanzmann, C Jacky, E Pichert, G Pestalozzi, B Marincek, B Sauter, C Honegger, H
Citation: Ra. Stahel et al., A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission, BR J HAEM, 104(4), 1999, pp. 763-769
Risultati: 1-16 |